Durvalumab Plus Chemo May be Promising Neoadjuvant Option in UTUC
Dr Patel on the Potential for Adjuvant Immunotherapy in CSCC
Observation Is a Reasonable Alternative to Adjuvant PD-1 Blockade in Stage IIB/IIIC Melanoma
Dr Oluwole on CRS and Neurotoxicity Beyond 2 Weeks After Axi-Cel Infusion in R/R LBCL
Ibrutinib/Venetoclax/Obinutuzumab Controls Disease at 5 Years in Newly Diagnosed MCL
Updated Clinical Trial Data Reflect Efforts to Optimize IO Combos in Non-ccRCC and MIBC, Fine-Tune ADT-Based Regimens in Prostate Cancer
Dr Lheureux on Advancements in Targeted Treatment Delivery for Ovarian Cancer
Data Continue to Reshape Treatment Considerations Across Advanced GI Malignancies
2 Commerce Drive
Cranbury, NJ 08512